{
    "clinical_study": {
        "@rank": "104219", 
        "arm_group": [
            {
                "arm_group_label": "SLIT of House Dust Mite (HDM) allergen extracts (A)", 
                "arm_group_type": "Experimental", 
                "description": "Sublingual Immunotherapy Tablets (SLIT) of HDM allergen extracts, 3 different doses (A)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets Matching the SLIT HDM allergen extracts"
            }, 
            {
                "arm_group_label": "SLIT of HDM allergen extracts", 
                "arm_group_type": "Experimental", 
                "description": "Sublingual Immunotherapy Tablets (SLIT) of HDM allergen extracts, 3 different doses (B)"
            }, 
            {
                "arm_group_label": "SLIT of HDM allergen extracts (C)", 
                "arm_group_type": "Experimental", 
                "description": "Sublingual Immunotherapy Tablets (SLIT) of HDM allergen extracts, 3 different doses (C)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of different doses of\n      sublingual tablets of house dust mite allergen extracts as compared to placebo in adults\n      with house dust mite-associated allergic asthma."
        }, 
        "brief_title": "Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Asthma", 
            "House Dust Mite Allergy"
        ], 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent.\n\n          -  Male or female from 18 to 50 years of age.\n\n          -  Diagnosed asthma and rhinitis with medical history consistent with HDM-induced\n             allergic asthma and rhinitis.\n\n          -  Positive SPT to HDM and and HDM-specific IgE serum value \u2265 0.7 kU/L.\n\n          -  Stable asthma therapies.\n\n          -  Spirometry (pre-bronchodilator) with best FEV1 \u2265 70% of the predicted value.\n\n          -  Spirometry with reversibility in FEV1 of \u2265 12% and \u2265 200 mL.\n\n          -  Asthma Control Test\u2122 (ACT) score \u2264 19.\n\n        Exclusion Criteria:\n\n          -  Former smoker with > 10 pack year history or current smoker.\n\n          -  Patient with a urine level of cotinine \u2265 500 ng/mL.\n\n          -  Co-sensitisation to any allergen possibly leading to clinically relevant symptoms\n             likely to significantly change the asthma symptoms of the subject during the study.\n\n          -  Patient who received allergen immunotherapy for HDM within the past 10 years.\n\n          -  Ongoing immunotherapy for an aeroallergen other than house dust mite.\n\n          -  Patient with any oral condition that could confound the safety assessments or\n             planning to have a dental extraction during the study.\n\n          -  Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase\n             inhibitors (MAOIs).\n\n          -  Pregnant women or breast-feeding/lactating.\n\n          -  Women with childbearing potential who are not using a medically accepted birth\n             control method.\n\n          -  Patient with a past or current disease, which as judged by the Investigator, may\n             affect the patient's participation in, or the outcome of this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930461", 
            "org_study_id": "VO72.12"
        }, 
        "intervention": [
            {
                "arm_group_label": "SLIT of House Dust Mite (HDM) allergen extracts (A)", 
                "intervention_name": "Biological/Vaccine: SLIT tablets of HDM allergen extracts (A)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Biological/Vaccine: Matching placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "SLIT of HDM allergen extracts", 
                "intervention_name": "Biological/Vaccine: SLIT tablets of HDM allergen extracts (B)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "SLIT of HDM allergen extracts (C)", 
                "intervention_name": "Biological/Vaccine: SLIT tablets of HDM allergen extracts (C)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHU Arnaud de Villeneuve"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67091"
                    }, 
                    "name": "NHC, H\u00f4pitaux Universitaires de Strasbourg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Universit\u00e4tsmedizin Berlin - Allergie-Centrum-Charit\u00e9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "zip": "90-153"
                    }, 
                    "name": "SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w \u0141odzi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarnow", 
                        "country": "Poland", 
                        "zip": "33-100"
                    }, 
                    "name": "Majorek-Olechowska Bernadetta"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Poland"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma", 
        "other_outcome": {
            "measure": "Changes of Immunological parameters (HDM-specific IgE and IgG4 values)", 
            "safety_issue": "No", 
            "time_frame": "13 months"
        }, 
        "overall_official": {
            "affiliation": "Montpellier, France", 
            "last_name": "Pascal Demoly, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Czech Republic: State Institute for Drug Control", 
                "Slovakia: State Institute for Drug Control", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Denmark: Danish Health and Medicines Authority", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Austria: Austrian Medicines and Medical Devices Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of the effect of one year of treatment of 3 different doses of sublingual immunotherapy tablets of house dust mite (HDM) allergen extracts as compared to placebo on the Asthma Control Test\u2122 (ACT) score, in adults with HDM-associated allergic asthma", 
            "measure": "Effect on the Asthma control test (ACT) score", 
            "safety_issue": "No", 
            "time_frame": "13 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Effect on the Rhinoconjunctivitis symptoms and rescue medication use", 
                "safety_issue": "No", 
                "time_frame": "Measured during the last 3 months of the trial"
            }, 
            {
                "measure": "Change from baseline on the Quality of Life using the AQLQ", 
                "safety_issue": "No", 
                "time_frame": "Measured during the last 6 months of the trial"
            }, 
            {
                "measure": "Number of asthma exacerbations", 
                "safety_issue": "No", 
                "time_frame": "Measured during the last 6 months of the trial"
            }, 
            {
                "measure": "Number and percentage of subjects with treatment-emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Measured during 13 months"
            }
        ], 
        "source": "Stallergenes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stallergenes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}